Base Year
Historical Year
Forecast Year
The male hypogonadism market size is expected to grow at a CAGR of 3.6% during the forecast period of 2025-2034, driven by the rising prevalence of male hypogonadism, growing elderly population size, and heightened awareness among patients across the 8 major markets.
Male hypogonadism is characterized by the low production of the male sex hormone testosterone, resulting in testosterone deficiency in the body. The prevalence of the condition is estimated to be 6% to 12% in the general population and is found to increase with age. It is reported that the prevalence rate of male hypogonadism is 40% in men having type 2 diabetes , suggesting a strong correlation between hypogonadism and type 2 diabetes. With the growing number of cases of testicular failure, the male hypogonadism market demand is projected to witness a surge in the forecast period.
The evolving regulatory frameworks characterised by surge in approvals from the health regulatory agencies are positively influencing the market growth. In October 2023, Eugia Pharma Specialities Limited, the subsidiary of Aurobindo Pharma , received its final approval from the United States Food and Drug Administration (FDA) to produce and commercialize Testosterone Cypionate injection. The product will be available in concentrations of 100 mg/mL and 200 mg/mL in multi-dose vials and 200 mg/mL in single-dose vials. The launch is scheduled for November 2023, and this is the 169th abbreviated new drug application (ANDA) approval received from Eugia Pharma Speciality Group (EPSG) facilities. Testosterone Cypionate injection is intended for replacement therapy in males with low or absent endogenous testosterone, such as primary hypogonadism.
The market is also driven by the growing geriatric population which is at a higher risk of developing male hypogonadism. In addition, the rising awareness among the patients coupled with investments and advancements in the healthcare sector will also fuel the market demand.
| Key Trend | Impact |
| Advancements in Testosterone Replacement Therapy (TRT) | The significant advancements in testosterone replacement therapy options, including oral medications, transdermal patches, gels, and injections have resulted in minimized side effects, and more stable testosterone levels. |
| Increasing Awareness and Diagnosis Rates | Heightened awareness among both patients and healthcare providers about male hypogonadism is leading to higher diagnosis rates and a larger patient population seeking treatment. |
| Development of Novel Therapeutics | The market is witnessing the development of novel therapeutic agents, including selective androgen receptor modulators (SARMs) and new hormone synthesis inhibitors, offering potential alternatives to traditional TRT. |
| Personalized Treatment Approaches | There is an increasing emphasis on personalized medicine within the market, focusing on individual patient needs, risk profiles, and preferences to optimize treatment outcomes. |
Market Breakup by Type
The market is segmented by type into primary hypogonadism and secondary hypogonadism. Primary hypogonadism involves dysfunction of the testes whereas secondary hypogonadism occurs due to a dysfunction in the hypothalamus or pituitary gland.
Market Breakup by Diagnosis
By diagnosis, the market is segmented into blood tests, imaging scans, genetic testing, and clinical evaluation. These diagnostic approaches help to determine appropriate treatment for individuals with hypogonadism.
Market Breakup by Therapy
The male hypogonadism market share offers therapies such as testosterone replacement therapy, selective estrogen receptor modulators (SERMs), hormone replacement therapy, and assisted reproductive technologies (ART). These therapies help to address the challenges associated with hypogonadism.
Market Breakup by Drug Delivery
The market for male hypogonadism is segmented by drug delivery methods into topical gels, injectables, transdermal patches, and others. This market segment represents diverse options available for administering testosterone replacement therapy and other treatment therapies.
Market Breakup by End User
The male hypogonadism market report provides an insight into end users of the market as well. It includes hospitals and clinics, specialty clinics, retail pharmacies, and other healthcare facilities. This market segment includes diverse healthcare settings that provide treatment options for patients with male hypogonadism.
Market Breakup by Region
Based on the region, the market includes the United States, EU-4 (Germany, France, Italy, Spain), the United Kingdom, Japan, and China. North America holds a high market value due to the rising cases of individuals with male hypogonadism. Furthermore, the rising awareness among patients and greater accessibility to treatment therapies are also driving the market demand.
Male Hypogonadism Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2018-2024 |
| Forecast Period | 2025-2034 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Diagnosis |
|
| Breakup by Therapy |
|
| Breakup by Drug Delivery |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The market is anticipated to grow at a CAGR of 3.6% during the forecast period of 2025-2034, driven by the rising prevalence of male hypogonadism, and elderly population base across the 8 major markets.
The market demand is driven by the rising disposable income and advancement in the healthcare sector.
One of the significant trends in the market is the surge in approvals from the health regulatory agencies. In October 2023, Aurobindo Pharma's subsidiary Eugia Pharma Specialities Limited received final approval from the United States FDA to produce and commercialize Testosterone Cypionate injection.
Based on the type, the market is divided into primary hypogonadism and secondary hypogonadism.
Drug delivery methods include topical gels, injectables, transdermal patches, and others.
The market offers therapies such as testosterone replacement therapy, selective estrogen receptor modulators (SERMs), hormone replacement therapy, and assisted reproductive technologies (ART).
Major end users of the market are hospitals and clinics, specialty clinics, retail pharmacies, and other healthcare facilities.
Diagnostic methods available in the market include blood tests, imaging scans, genetic testing, and clinical evaluation.
The major regions of the market include the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and China.
Key players involved in the market are Lipocine Inc., Pfizer Inc., AbbVie Inc., Aytu BioPharma Inc., Merck & Co., Inc., Laboratoires Genevrier, Ferring, Perrigo Company plc, Eli Lilly, Bayer AG, Endo International plc., Allergan plc, Bristol-Myers Squibb Company, AstraZeneca PLC, and IBSA Institute Bio Chimique SA.
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,969
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share